Thus, our work provides the proof of concept that pharmaceutical intervention of the TRIM56/FASN axis could be a clinically translatable approach to rescue the systemically deregulated lipid metabolism observed in NAFLD. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.